Literature DB >> 17414107

Ovarian sertoli-leydig cell tumors with pseudoendometrioid tubules (pseudoendometrioid sertoli-leydig cell tumors).

W Glenn McCluggage1, Robert H Young.   

Abstract

The propensity for ovarian endometrioid adenocarcinomas to morphologically mimic Sertoli, Sertoli-Leydig, and granulosa cell tumors, is well known. The converse situation, mimicry of an endometrioid neoplasm by a sex cord-stromal tumor, has not been emphasized. In this report, we describe 9 ovarian Sertoli-Leydig cell tumors (5 well differentiated, 4 of intermediate differentiation) with areas containing hollow, sometimes dilated, tubules which resemble endometrioid glands; we refer to these as pseudoendometrioid tubules. The age of the patients ranged from 14 to 57. The tumors, all of which were unilateral except for one, ranged from 3.5 to 19 cm and were variously described as tan, pale, yellow, or gold. The proportion of the tumor made up of pseudoendometrioid tubules ranged from 10% to >90%. When widespread, their presence sometimes resulted in consideration of a borderline endometrioid adenofibroma or a well-differentiated endometrioid adenocarcinoma. However, all the neoplasms contained typical Sertoli tubules and one or more of the characteristic patterns of Sertoli-Leydig cell tumors as well as Leydig cells, although the latter cells were inconspicuous in some cases. Immunohistochemistry, performed in 4 cases, showed that the pseudoendometrioid tubules, as well as the more typical Sertoli cell elements, were either positive for alpha inhibin (3 of 4 cases) or calretinin (3 of 4 cases) or both, although sometimes focally so. These elements were negative with epithelial membrane antigen and cytokeratin 7. In all 4 cases, the pseudoendometrioid tubules were positive with the broad spectrum cytokeratin AE1/3. This report illustrates the potential for ovarian Sertoli-Leydig cell tumors to contain tubules with a pseudoendometrioid appearance which mimic a borderline or malignant endometrioid neoplasm. The presence of more typical Sertoli cell elements and Leydig cells, an absence of squamous elements, endometriosis or associated adenofibroma, and the characteristic immunophenotype assist in diagnosis.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17414107     DOI: 10.1097/01.pas.0000213365.56498.72

Source DB:  PubMed          Journal:  Am J Surg Pathol        ISSN: 0147-5185            Impact factor:   6.394


  6 in total

1.  Endocrine pathology of the ovary : in tribute to Robert E Scully, MD.

Authors:  Esther Oliva; Robert H Young
Journal:  Endocr Pathol       Date:  2014-03       Impact factor: 3.943

Review 2.  Sertoli-Leydig cell tumor with heterologous element: a case report and a review of the literature.

Authors:  Longwen Chen; Cairo Dana Tunnell; Giovanni De Petris
Journal:  Int J Clin Exp Pathol       Date:  2014-02-15

Review 3.  Data set for reporting of ovary, fallopian tube and primary peritoneal carcinoma: recommendations from the International Collaboration on Cancer Reporting (ICCR).

Authors:  W Glenn McCluggage; Meagan J Judge; Blaise A Clarke; Ben Davidson; C Blake Gilks; Harry Hollema; Jonathan A Ledermann; Xavier Matias-Guiu; Yoshiki Mikami; Colin J R Stewart; Russell Vang; Lynn Hirschowitz
Journal:  Mod Pathol       Date:  2015-06-19       Impact factor: 7.842

Review 4.  [Grading of gynecological tumors : Current aspects].

Authors:  L-C Horn; D Mayr; C E Brambs; J Einenkel; I Sändig; K Schierle
Journal:  Pathologe       Date:  2016-07       Impact factor: 1.011

5.  Poorly Differentiated Thyroid Carcinoma Arising in Struma Ovarii.

Authors:  Surapan Khunamornpong; Jongkolnee Settakorn; Kornkanok Sukpan; Prapaporn Suprasert; Sumalee Siriaunkgul
Journal:  Case Rep Pathol       Date:  2015-06-21

6.  Estrogen-producing endometrioid adenocarcinoma resembling sex cord-stromal tumor of the ovary: a review of four postmenopausal cases.

Authors:  Tomomi Katoh; Masanori Yasuda; Kosei Hasegawa; Eito Kozawa; Jun-ichi Maniwa; Hironobu Sasano
Journal:  Diagn Pathol       Date:  2012-11-28       Impact factor: 2.644

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.